Cerebral dysfunction in the intensive care unit: a package deal?
Spronk
Peter E
PE
D000698:Analgesia / Q000009:adverse effects / Q000379:methods*; D000700:Analgesics / Q000009:adverse effects / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000627:therapeutic use; D057189:Checklist; D002985:Clinical Protocols; D003128:Coma / Q000139:chemically induced / Q000401:mortality / Q000517:prevention & control*; D003422:Critical Care / Q000379:methods*; D016638:Critical Illness; D003704:Dementia / Q000139:chemically induced / Q000401:mortality / Q000517:prevention & control*; D006801:Humans; D006993:Hypnotics and Sedatives / Q000009:adverse effects / Q000627:therapeutic use*; D007049:Iatrogenic Disease; D007362:Intensive Care Units; D007902:Length of Stay; D010147:Pain Measurement; D012121:Respiration, Artificial; D018570:Risk Assessment; D012307:Risk Factors; D013997:Time Factors
D000700:Analgesics; D014150:Antipsychotic Agents; D006993:Hypnotics and Sedatives